相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial
Alice Boileve et al.
EUROPEAN JOURNAL OF CANCER (2021)
Mismatch Repair Protein Deficiency/Microsatellite Instability Is Rare in Cholangiocarcinomas and Associated With Distinctive Morphologies
Jennifer Y. Ju et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2020)
Systemic therapies for intrahepatic cholangiocarcinoma
Robin Kate Kelley et al.
JOURNAL OF HEPATOLOGY (2020)
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies
Sarina A. Piha-Paul et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial
Luis Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer
Richard D. Kim et al.
JAMA ONCOLOGY (2020)
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer
Changhoon Yoo et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
New Treatment Options for Advanced Biliary Tract Cancer
Jonathan D. Mizrahi et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2020)
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies
Lijie Zhai et al.
FRONTIERS IN IMMUNOLOGY (2020)
Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study
Sang Hoon Lee et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma
Jianzhen Lin et al.
HEPATOBILIARY SURGERY AND NUTRITION (2020)
Molecular profile of BRCA-mutated biliary tract cancers
Gilbert Spizzo et al.
ESMO OPEN (2020)
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
Soomin Ahn et al.
SCIENTIFIC REPORTS (2020)
Microsatellite Instability-high Intrahepatic Cholangiocarcinoma with Portal Vein Tumor Thrombosis Successfully Treated with Pembrolizumab
Atsushi Naganuma et al.
INTERNAL MEDICINE (2020)
Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look
Angela Dalia Ricci et al.
CANCER CONTROL (2020)
The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma
Yun Wang et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2019)
Survival after Resection of Multiple Tumor Foci of Intrahepatic Cholangiocarcinoma
Stefan Buettner et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2019)
Cholangiocarcinoma: Epidemiology and risk factors
Shahid A. Khan et al.
LIVER INTERNATIONAL (2019)
Interferons α and β in cancer: therapeutic opportunities from new insights
Ernest C. Borden
NATURE REVIEWS DRUG DISCOVERY (2019)
Hepatitis C Virus Infection and Cholangiocarcinoma An Insight into Epidemiologic Evidences and Hypothetical Mechanisms of Oncogenesis
Maria-Cristina Navas et al.
AMERICAN JOURNAL OF PATHOLOGY (2019)
Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Weiqiang Zhou et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
Makoto Ueno et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2019)
Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis A case report and literature review
Wei-xun Chen et al.
MEDICINE (2019)
Actual 5-Year Survivors After Surgical Resection of Hilar Cholangiocarcinoma
Thuy B. Tran et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism
Jingjing Zhu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Immunobiology of cholangiocarcinoma
Emilien Loeuillard et al.
JHEP REPORTS (2019)
Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets
David K. Lau et al.
ISCIENCE (2019)
Cholangiocarcinoma - evolving concepts and therapeutic strategies
Sumera Rizvi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma
Massimiliano Cadamuro et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)
Hendrik-Tobias Arkenau et al.
ONCOLOGIST (2018)
Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair
Angela Lamarca et al.
CANCER TREATMENT REVIEWS (2018)
Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report
Haibo Mou et al.
BMC CANCER (2018)
Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell
Manping Huang et al.
BMC GASTROENTEROLOGY (2018)
Nivolumab for the treatment of hepatocellular carcinoma
Fabian Finkelmeier et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies
Anna Minchom et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers
Yelei Guo et al.
CLINICAL CANCER RESEARCH (2018)
PD-L1 expression in extrahepatic cholangiocarcinoma
Dirk Walter et al.
HISTOPATHOLOGY (2017)
Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma
Kai-chao Feng et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma
Ke Ma et al.
ONCOLOGY LETTERS (2017)
PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
Jacqueline Fontugne et al.
ONCOTARGET (2017)
Assessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors
Solmaz Sahebjam et al.
CANCER CONTROL (2017)
Role of tumor microenvironment in tumorigenesis
Maonan Wang et al.
JOURNAL OF CANCER (2017)
Successful immune checkpoint blockade in a patient with advanced stage microsatellite-unstable biliary tract cancer
Elena Czink et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2017)
Immunotherapeutic Approaches to Biliary Cancer
Urvi A. Shah et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2017)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma
Faiz Gani et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice
Apurva Jain et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2016)
Forty-Year Trends in Cholangiocarcinoma Incidence in the US: Intrahepatic Disease on the Rise
Supriya K. Saha et al.
ONCOLOGIST (2016)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
David H. Munn et al.
TRENDS IN IMMUNOLOGY (2016)
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce et al.
SCIENCE (2015)
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study
A. Santoro et al.
ANNALS OF ONCOLOGY (2015)
Intrahepatic cholangiocarcinoma and cholangiolocellular carcinoma in cirrhosis and chronic viral hepatitis
Shun-ichi Ariizumi et al.
SURGERY TODAY (2015)
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme
M. Moehler et al.
EUROPEAN JOURNAL OF CANCER (2014)
Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer
B. Goeppert et al.
BRITISH JOURNAL OF CANCER (2013)
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Sumera Rizvi et al.
GASTROENTEROLOGY (2013)
Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer
Masanori Kobayashi et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2013)
The role of the hepatitis viruses in cholangiocarcinoma
S. Ralphs et al.
JOURNAL OF VIRAL HEPATITIS (2013)
Hepatitis B virus infection increases the risk of cholangiocarcinoma: A meta-analysis and systematic review
Min Li et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2012)
Risk Factors for Cholangiocarcinoma
Gia L. Tyson et al.
HEPATOLOGY (2011)
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells
Barbara Molon et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
C. Bengala et al.
BRITISH JOURNAL OF CANCER (2010)
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer.
Juan Valle et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Cholangiocarcinoma - Thirty-one-year experience with 564 patients at a single institution
Michelle L. DeOliveira et al.
ANNALS OF SURGERY (2007)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
分享论文
